Navigation Links
Plato BioPharma Presenting Poster at the American Thoracic Society Conference
Date:5/4/2011

WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc. will be jointly presenting a thematic poster at the "Novel Therapeutics in Pulmonary Fibrosis" session at the 2011 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 18, 2011.  The poster entitled Differing Effects of Ambrisentan and Bosentan on Pulmonary Fibrosis and Lung Mechanics Following Bleomycin Instillation will be presented by John Liles, PhD of Gilead Sciences, Inc. and  Craig Plato, PhD, CEO of Plato BioPharma, Inc.

"Human Idiopathic Pulmonary Fibrosis has no known effective treatment, and a dramatically poor prognosis," said Dr. Plato.  "The thematic research being presented at the 2011 ATS Conference provides insights into differential benefit of selective versus non-selective endothelin receptor antagonists in a robust preclinical model of this debilitating disease.  Importantly, for the first time, clinically-relevant functional endpoints such as arterial blood gases, lung function, and pulmonary hemodynamics have been utilized, in part, to reveal the benefit of selective endothelin receptor antagonism."

"One of PBI's key strengths is to leverage and impart our years of experience, expertise, and technology for every study we conduct.  This approach offers clients an advantage over a typical contract research organization or functional service provider relationship.  We strive to be an integral partner with our clients, delivering cutting-edge, high-resolution disease modeling and methods as well as insightful solutions to preclinical drug discovery challenges," said Dr. Plato.  "I believe our joint presentation with Gilead at this year's ATS shows our commitment to these goals and value-add for our clients."

Founded in 2009, Plato BioPharma, Inc is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution engagements ranging from pharmacokinetics through disease model and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.


'/>"/>
SOURCE Plato BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. New PLATO Sub-Analysis of CABG Patients Presented at ACC
3. Plato BioPharma, Inc Appoints New Board Member
4. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - Industry Forecast to 2025" report to their offering. ... The Global Wireless ... 23.8% over the next decade to reach approximately $330.5 billion by ... forecasts for all the given segments on global as well as ...
(Date:2/24/2017)... 2017 Physician General Dr. Rachel Levine ... Jennifer Smith commended South Central EMS today ... using naloxone, a life-saving overdose reversal drug. The recognition ... specialist and overdose survivor who was saved due to ... "A significant part of fighting the opioid epidemic is ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 Report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through ... markets. Market data and analytics are derived from primary and ...
Breaking Medicine Technology:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... of Liberty University, has officially announced the appointment of Peter A. Bell, DO, ... of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An ... true account of his paramedic experiences. Schanssema describes the tragedies he saw, as well ... to overcome them. , Schanssema, initially unsure of the career path he wanted to ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
Breaking Medicine News(10 mins):